JP7398455B2 - ピラゾロンホルミルペプチド２受容体アゴニスト - Google Patents
ピラゾロンホルミルペプチド２受容体アゴニスト Download PDFInfo
- Publication number
- JP7398455B2 JP7398455B2 JP2021529452A JP2021529452A JP7398455B2 JP 7398455 B2 JP7398455 B2 JP 7398455B2 JP 2021529452 A JP2021529452 A JP 2021529452A JP 2021529452 A JP2021529452 A JP 2021529452A JP 7398455 B2 JP7398455 B2 JP 7398455B2
- Authority
- JP
- Japan
- Prior art keywords
- difluoro
- methoxyphenyl
- amino
- pyrrolidin
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/423—Oxazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862771196P | 2018-11-26 | 2018-11-26 | |
| US62/771,196 | 2018-11-26 | ||
| US201962819832P | 2019-03-18 | 2019-03-18 | |
| US62/819,832 | 2019-03-18 | ||
| PCT/US2019/062905 WO2020112583A1 (en) | 2018-11-26 | 2019-11-25 | Pyrrolidinone derivatives as formyl peptide 2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022508218A JP2022508218A (ja) | 2022-01-19 |
| JP2022508218A5 JP2022508218A5 (enExample) | 2022-12-02 |
| JP7398455B2 true JP7398455B2 (ja) | 2023-12-14 |
Family
ID=68848531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529452A Active JP7398455B2 (ja) | 2018-11-26 | 2019-11-25 | ピラゾロンホルミルペプチド２受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12281108B2 (enExample) |
| EP (1) | EP3887366B1 (enExample) |
| JP (1) | JP7398455B2 (enExample) |
| KR (1) | KR102877973B1 (enExample) |
| CN (1) | CN113166134B (enExample) |
| ES (1) | ES2964299T3 (enExample) |
| WO (1) | WO2020112583A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL299680A (en) | 2020-07-09 | 2023-03-01 | Bristol Myers Squibb Co | Pyrazolone formyl peptide 2 receptor agonists |
| JP7771157B2 (ja) * | 2020-07-09 | 2025-11-17 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン ｆｐｒ２アゴニスト |
| JP7802765B2 (ja) * | 2020-08-12 | 2026-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | オキソピロリジン尿素ｆｐｒ２アゴニスト |
| KR20230084530A (ko) * | 2020-10-09 | 2023-06-13 | 브리스톨-마이어스 스큅 컴퍼니 | 아미노이미다졸 fpr2 효능제 |
| WO2022155859A1 (en) * | 2021-01-21 | 2022-07-28 | Beijing Tiantan Hospital | Modulators of fpr1 and methods of using the same |
| JP7717816B2 (ja) * | 2021-01-21 | 2025-08-04 | バイオフロント セラピューティクス （ベイジン） カンパニー リミテッド | Ｆｐｒ１のモジュレーター及びそれを使用する方法 |
| WO2022193187A1 (en) * | 2021-03-17 | 2022-09-22 | Biofront Ltd. (Cayman) | Modulators of fpr1 and methods of using same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015079692A1 (ja) | 2013-11-28 | 2015-06-04 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| WO2018054549A1 (en) | 2016-09-21 | 2018-03-29 | Grünenthal GmbH | 6-membered cyclic amines or lactames substituted with urea and phenyl |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6746613B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| JP6746614B2 (ja) | 2015-05-27 | 2020-08-26 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| CN108348479A (zh) | 2015-11-24 | 2018-07-31 | 百时美施贵宝公司 | 靶向甲酰肽受体2/脂氧素a4受体(fpr2/alx)以用于治疗心脏疾病 |
| EP3414227B1 (en) | 2015-12-10 | 2021-11-24 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP2020015664A (ja) * | 2016-11-21 | 2020-01-30 | 宇部興産株式会社 | 含窒素多環式ヘテロ環誘導体 |
| WO2018213572A1 (en) * | 2017-05-17 | 2018-11-22 | William Marsh Rice University | Preparation of secondary amines with electrophilic n-linchpin reagents |
| KR102623473B1 (ko) | 2017-06-09 | 2024-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 |
| WO2018227067A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Cyclopropyl urea formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| CN110997653B (zh) | 2017-06-09 | 2023-06-06 | 百时美施贵宝公司 | 芳基杂环哌啶酮甲酰肽2受体和甲酰肽1受体激动剂 |
| US11008301B2 (en) | 2017-06-09 | 2021-05-18 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor agonists |
| US10676431B2 (en) | 2018-03-05 | 2020-06-09 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| WO2020257161A1 (en) | 2019-06-18 | 2020-12-24 | Bristol-Myers Squibb Company | Biaryl dialkyl phosphine oxide fpr2 agonists |
-
2019
- 2019-11-25 CN CN201980077329.9A patent/CN113166134B/zh active Active
- 2019-11-25 WO PCT/US2019/062905 patent/WO2020112583A1/en not_active Ceased
- 2019-11-25 JP JP2021529452A patent/JP7398455B2/ja active Active
- 2019-11-25 US US17/295,092 patent/US12281108B2/en active Active
- 2019-11-25 KR KR1020217019403A patent/KR102877973B1/ko active Active
- 2019-11-25 ES ES19818484T patent/ES2964299T3/es active Active
- 2019-11-25 EP EP19818484.8A patent/EP3887366B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015079692A1 (ja) | 2013-11-28 | 2015-06-04 | 杏林製薬株式会社 | ウレア誘導体、またはその薬理学的に許容される塩 |
| WO2018054549A1 (en) | 2016-09-21 | 2018-03-29 | Grünenthal GmbH | 6-membered cyclic amines or lactames substituted with urea and phenyl |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022508218A (ja) | 2022-01-19 |
| CN113166134A (zh) | 2021-07-23 |
| CN113166134B (zh) | 2024-06-14 |
| KR102877973B1 (ko) | 2025-10-30 |
| EP3887366B1 (en) | 2023-09-27 |
| WO2020112583A1 (en) | 2020-06-04 |
| KR20210095897A (ko) | 2021-08-03 |
| US12281108B2 (en) | 2025-04-22 |
| US20220002281A1 (en) | 2022-01-06 |
| EP3887366A1 (en) | 2021-10-06 |
| ES2964299T3 (es) | 2024-04-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7398455B2 (ja) | ピラゾロンホルミルペプチド２受容体アゴニスト | |
| US11530183B2 (en) | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists | |
| KR102623473B1 (ko) | 피페리디논 포르밀 펩티드 2 수용체 및 포르밀 펩티드 1 수용체 효능제 | |
| JP7476216B2 (ja) | ファルネソイドｘ受容体モジュレータとしての置換二環式化合物 | |
| CN116034104B (zh) | 氧代吡咯烷fpr2激动剂 | |
| ES2986512T3 (es) | Agonistas del receptor 2 del péptido formil pirazolona | |
| CN116057055B (zh) | 氧代吡咯烷脲类fpr2激动剂 | |
| US20230373930A1 (en) | Aminoimidazole fpr2 agonists | |
| EA047337B1 (ru) | Замещенные бициклические соединения в качестве модуляторов фарнезоидного х-рецептора |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221124 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221124 |
|
| TRDD | Decision of grant or rejection written | ||
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231124 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231128 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20231204 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7398455 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |